Comparative Pharmacology
Head-to-head clinical analysis: ATROPINE AND DEMEROL versus ROXIPRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATROPINE AND DEMEROL versus ROXIPRIN.
ATROPINE AND DEMEROL vs ROXIPRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atropine is an antimuscarinic agent that competitively blocks acetylcholine at muscarinic receptors, reducing secretions and gastrointestinal motility. Meperidine (Demerol) is an opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception and producing analgesia.
Roxiprin is a combination analgesic containing rofecoxib (a COX-2 selective NSAID) and paracetamol (acetaminophen, a centrally acting analgesic/antipyretic). Rofecoxib inhibits prostaglandin synthesis by selectively blocking cyclooxygenase-2, reducing pain and inflammation. Paracetamol inhibits cyclooxygenase in the central nervous system and modulates descending serotonergic pathways, providing analgesia and antipyresis.
Atropine 0.4 mg and Demerol (meperidine) 50-100 mg intramuscularly as preanesthetic medication 30-60 minutes before procedure.
500 mg orally every 6 to 8 hours as needed for pain or fever; maximum 2000 mg per day.
None Documented
None Documented
Atropine: 2-4 hours (terminal half-life). Demerol: 2.5-4 hours; normeperidine metabolite half-life 15-30 hours (accumulates in renal impairment).
2.5 hours (prolonged to 4-6 hours in hepatic impairment; no significant change in renal impairment)
Atropine: approximately 50% excreted unchanged in urine, remainder as metabolites (biliary and renal). Demerol (meperidine): primarily hepatic metabolism; <5% excreted unchanged in urine; metabolites (including normeperidine) excreted renally.
Renal (70% as unchanged drug, 20% as glucuronide conjugate); biliary/fecal (10%)
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination